RNA-targeting drugs behind Roche’s acquisition of Santaris
New drugs that target ribonucleic acid (RNA) being developed by Danish biotechnology company Santaris Pharma lie behind the decision by Roche to buy Santaris that was announced yesterday, August 4.
AstraZeneca sues Zydus to protect Nexium
Anglo-Swedish pharmaceutical company AstraZeneca has sued India-based Zydus for infringing three patents related to its heartburn drug Nexium (esomeprazole magnesium).
Boehringer sues Mylan over aspirin product
German pharmaceutical company Boehringer Ingelheim has sued generic drug maker Mylan for infringing a patent covering its Aggrenox drug.
Pfizer acquires Baxter vaccines for $635m
Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.
Pfizer profits hit by Viagra patent expiration
The expiration of US pharmaceutical company Pfizer’s patent for Viagra in many European countries was a contributing factor to the drop in revenue that it reported yesterday (July 29) when releasing its second-quarter earnings data.
AstraZeneca boosts patent portfolio with lung drug acquisition
UK-based pharmaceutical company AstraZeneca has boosted its patent portfolio with the acquisition of rights to Spanish company Almirall’s lung drugs, including Eklira (aclidinium).
DLA Piper recruits life sciences lawyer for Silicon Valley
DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.
FDA accepts Sandoz biosimilar application
US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind.
Justice Arnold U-turns on Pharmacia case
Justice Arnold of the England and Wales High Court has decided to reverse a previous decision and grant Pfizer subsidiary Pharmacia its application to stay Actavis’s patent revocation action against it.
Dechert hires new life sciences partner
Law firm Dechert LLP has bolstered its life sciences team with the hire of Scott Warren as a partner in its IP practice in New York.
